Le Lézard
Classified in: Health
Subjects: PDT, FDA

U.S. Food and Drug Administration Clears UVision360, Inc. Novel LUMINELLE® 360° Bx (Biopsy) Sheath

RALEIGH, N.C., July 7, 2021 /PRNewswire/ -- UVision360, Inc., an innovative medical device company, announces today that the U.S. Food and Drug Administration (FDA) has approved the patented LUMINELLE 360° Bx (Biopsy) Sheath which expands the capability of the LUMINELLE® DTx System.  The LUMINELLE 360° Bx sheath, combined with the LUMINELLE DTx System, is the first and only integrated directed biopsy device not requiring the use of additional instruments, and indicated for uterine and bladder biopsies. The LUMINELLE DTx System is an endoscopic platform assisting both male/female procedures, bringing operating room capabilities affordably to physician offices so bladder and uterine tissue samples can be obtained easily with visualization.

The first and only integrated directed biopsy device not requiring the use of additional instruments

"The FDA approval of our LUMINELLE Bx Sheath not only marks a major milestone for UVision360 but is also a game changer when it comes to the standard of care for tissue biopsy procedures," said UVision360 CEO Allison London Brown. "The affordability, reusability, and adaptability of the LUMINELLE DTx System enhances the patient experience and gives doctors the flexibility to perform needed procedures when and where they see fit."

"Prior to the LUMINELLE Bx Sheath, doctors could not visualize and sample abnormal tissue without the use of additional biopsy tools," said Dr. David Robinson, UVision360's Chief Medical Officer. "Now, doctors will be able to easily visualize areas of concern, while sampling occurs. In addition, the clear biopsy sampling tube allows the physician to see how much actual tissue they are acquiring, ensuring they have an adequate sample. Taking directed tissue samples helps doctors and patients and arrange for follow up treatment sooner rather than later. A patient can have increased confidence in their diagnosis while the simplicity of the equipment makes the procedure more convenient and less challenging for the physician. The new biopsy sheath and improved reimbursement codes ensure doctors can provide superior medical coverage and help fill a critical unmet need."

The LUMINELLE DTx System is FDA cleared for both diagnostic and operative hysteroscopy and cystoscopy. Health professionals can perform office procedures for uterine, bladder health, without a prohibitive investment in equipment and provides convenience to office staff and patients, cost savings and addresses limitations  with current disposable devices on the market.

UVision360 will bring the new LUMINELLE Bx Sheath to market with a limited launch in Q3 of 2021, for use with the LUMINELLE DTx System and plans a broader distribution shortly thereafter.

About UVision360

UVision360, Inc. is dedicated to advancing access to care for men and women by transitioning procedures from the operating room to their physician's office. The company has created the LUMINELLE DTx System, a simplified, compact, and modular endoscopic system employing the latest in high?tech optics and interchangeable accessories to meet the needs of physicians and patients. More information about the LUMINELLE DTx System can be found by contacting info@UVision360.com or visiting www.luminelle360.com.

SOURCE UVision360, Inc

These press releases may also interest you

at 06:35
Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 million....

at 06:30
Given that 99% of children supported by Marie-Vincent know their abuser, the Foundation is officially launching Overcoming the unimaginable, rediscovering hope, an awareness campaign that aims to bring issues relating to sexual violence toward...

at 06:30
ViewRay, Inc. today announced that Helsinki University Hospital has purchased a MRIdian® System to offer patients MR-guided radiation therapy at the Comprehensive Cancer Center in the new Bridge Hospital. The Comprehensive Cancer Center is Finland's...

at 06:30
Resilia Pharmaceuticals, Inc. announced the signing today of a license agreement with Pelle Ventures, LLC granting Resilia the rights to make, market and sell Solacetm Eczema Cream, a medical device, as an OTC product in the United States. Financial...

at 06:05
Merck , known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the European Medicines Agency (EMA) has initiated a rolling review for molnupiravir, an investigational oral antiviral medicine, for the...

at 06:02
Following the successful and well-received Allograft line, Neoss is excited to announce the addition of NeoGenix XPtm this autumn to our existing product portfolio. NeoGenix XPtm is a safe and clinically proven natural bone substitute, that closer...

News published on 7 july 2021 at 07:35 and distributed by: